Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
Holding ROIV?
Track your performance easily
ROIV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.69 - $13.06
Previous CloseN/A
Volume1.46M
Average Volume (3M)4.84M
Market Cap
$8.13B
Enterprise Value$3.58B
Total Cash (Recent Filing)$2.06B
Total Debt (Recent Filing)$232.66M
Price to Earnings (P/E)2.0
Beta1.02
Next Earnings
Feb 17, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.66
Shares Outstanding727,949,770
10 Day Avg. Volume4,615,116
30 Day Avg. Volume4,844,413
Standard Deviation0.20
R-Squared0.15
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)64.70
Price to Cash Flow (P/CF)-7.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue28.46
Enterprise Value/Gross Profit32.75
Enterprise Value/Ebitda0.79
Forecast
1Y Price Target
$18.00Price Target Upside61.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Roivant Sciences News
PremiumCompany Announcements
Roivant Sciences Ends Namilumab Study Due to Inefficacy
PremiumCompany Announcements
Roivant Sciences Reports Q2 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Executive IncentivesThe investment community may be underestimating ROIV's executive incentive compensation structure, which is fully aligned with shareholders.
Financial PerformanceROIV has a very strong cash position and fundamentally de-risked pipeline programs.
Product DevelopmentBrepocitinib demonstrated better treatment failure results with a shorter steroid taper compared to previous studies, indicating potential to become the standard of care in non-infectious uveitis.
Bears Say
Clinical TrialsROIV announced that GM-CSF candidate namilumab failed to demonstrate treatment benefit in its Ph2 study in patients with pulmonary sarcoidosis, and the company will discontinue further development.
Financial PerformanceThe company revised FY25E EPS from -$0.67 to -$0.73.
Revenue And SalesThe revenue miss was confounded by the sale of Dermavant which moved Vtama revenues to discontinued ops and contributed to a non-GAAP net loss of ($219M).
---
Ownership Overview
18.32% Insiders
12.35% Mutual Funds
0.03% Other Institutional Investors
55.76% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ROIV FAQ
What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $9.69 and its highest was $13.05 in the past 12 months.
What is Roivant Sciences’s market cap?
Roivant Sciences’s market cap is $8.13B.
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s upcoming earnings report date is Feb 17, 2025 which is in 19 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on Nov 12, 2024. The company reported -$0.285 earnings per share for the quarter, missing the consensus estimate of -$0.247 by -$0.038.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -0.25.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 727,949,770 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of -$0.285 in its last earnings report, missing expectations of -$0.247. Following the earnings report the stock price went down -1.439%.
Which hedge fund is a major shareholder of Roivant Sciences?
Currently, no hedge funds are holding shares in ROIV
---
Roivant Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (61.43% Upside)
$18.00 (61.43% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 14.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.40%
12-Months-Change
Fundamentals
Return on Equity
159.08%
Trailing 12-Months
Asset Growth
200.46%
Trailing 12-Months
Company Description
Roivant Sciences
Montes Archimedes Acquisition Corp is a blank check company.
---
ROIV Company Deck
---
ROIV Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial and strategic position for Roivant, with significant positive developments in clinical data and capital acquisition. However, challenges remain in prescription growth for VTAMA and pressure on strategic capital use.Read More>---
ROIV Stock 12 Month Forecast
Average Price Target
$18.00
▲(61.43% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Biohaven Ltd.
―
Best Analysts Covering ROIV
1 Year
1 Year Success Rate
12/12 ratings generated profit
1 Year Average Return
+71.86%
reiterated a buy rating 8 months ago
Copying Louise Chen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +71.86% per trade.
---